Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Imaging experts debate link between CT scans, cancer risk

August 10, 2010
By Greg Frieherr
Greg Frieherr
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 8
Volume 19
Issue 8

Clinical studies examining the potential of CT exposure to cause cancer are under way, but it could be years or even a decade until the results are known, and even then, they may be inconclusive.

Clinical studies examining the potential of CT exposure to cause cancer are under way, but it could be years or even a decade until the results are known, and even then, they may be inconclusive.

A half dozen clinical studies are now enrolling hundreds of thousands of patients in Canada, the UK, Australia, Israel, Sweden, and France with the goal of looking specifically at whether CT is a cause of cancer. But the studies, mostly involving pediatric patients, will take many years to complete. And there is no guarantee the results will be definitive.

Andrew J. Einstein, MD, PhD, an assistant professor of clinical medicine in the departments of radiology and cardiology at New York's Columbia University, examined the current basis for concerns about radiation exposure from CT, noting that none of the data used to support these cautionary arguments involve CT radiation exposure itself. Instead they are largely drawn from studies examining survivors of the atomic bombing of Hiroshima, nuclear industry workers, and exposure of children to radiation in utero. "But it is still important that we do such studies because each additional study provides us with new information and a more complete picture of the issues that we are dealing with," Dr. Einstein said.


ANDREW J. EINSTEIN, MD, PHD

In the meantime, the CT community and the public will be left with only circumstantial data to make or break the connection between CT exams and cancer, a prospect that concerns Cynthia H. McCollough, PhD, director of the CT Clinical Innovation Center at the Mayo Clinic College of Medicine in Rochester, Minn.

Some patients are making poor decisions about their healthcare because of their unjustified fear of CT radiation, Dr. McCollough said, promulgated by data with considerable uncertainty. Despite 60 years of studying the A-bomb survivors, for example, no definitive conclusions have yet been made about the cancer risk at the relatively low doses commonly encountered during CT studies.

"When people say we just don't know what's happening, I disagree," she said. "We know that it is not a big effect. If it is an effect at all, it is a really small effect."

Dr. McCollough has a simple solution to the debate over radiation dose and CT, as it relates to deciding whether to schedule an exam. "If the CT is needed, do it, and do it carefully," she said. "And if it's not needed, don't do it."

References:

Source: 2010 International Symposium for Multidetector CT, International Society for Computed Tomography.

Articles in this issue

Colorectal cancer patients with vitamin D deficiency see worse outcomes
What is the Clinical Role of Induction Therapy in Locally Advanced Squamous Cell Cancer of the Head and Neck?
What is the Clinical Role of Induction Therapy in Locally Advanced Squamous Cell Cancer of the Head and Neck?
Who's News
Sonography better to monitor small testicular lesions
FDA Panel Says No More Avastin in Breast Cancer
Cell-signaling pathway may be new Rx target ER+ breast cancer
Evidence-based pathway plus electronic health records system matches major trials for colorectal cancer treatment outcomes
Ohio cancer center breaks ground on $1 billion addition
Second-Generation TKIs Poised to Succeed Imatinib in Newly Diagnosed CML
Imaging experts debate link between CT scans, cancer risk
From the ONI archives: CML patients’ molecular response to nilotinib continues to deepen over time
Smartphones hustle to maintain pace with rapid rate of change in oncology
Making comparative effectiveness work in cancer care
Geriatric assessment, communication skills essential for older patients
Patients look for answers on Web but trust it less

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
5 experts are featured in this series
4 experts in this video
2 experts are featured in this series.
4 experts in this video
4 experts in this video
4 experts in this video
2 experts are featured in this series.
5 experts are featured in this series
Related Content

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Russ Conroy
July 25th 2025
Article

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


The 2025 ASCO Annual Meeting showcased groundbreaking oncology research and treatments, fostering collaboration among leading experts in the field.

Top Trials From the 2025 ASCO and EHA Meetings

Julie M. Vose, MD, MBA
July 25th 2025
Article

The 2025 ASCO Annual Meeting showcased groundbreaking oncology research and treatments, fostering collaboration among leading experts in the field.


A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Related Content

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Russ Conroy
July 25th 2025
Article

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


The 2025 ASCO Annual Meeting showcased groundbreaking oncology research and treatments, fostering collaboration among leading experts in the field.

Top Trials From the 2025 ASCO and EHA Meetings

Julie M. Vose, MD, MBA
July 25th 2025
Article

The 2025 ASCO Annual Meeting showcased groundbreaking oncology research and treatments, fostering collaboration among leading experts in the field.


A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.